Publication

Article

Supplements and Featured Publications
Recent Advances in the Evolving Treatment Landscape of Melanoma

Recent Advances in the Evolving Treatment Landscape of Melanoma

Key Takeaways

  • It's really interesting that it has a lot of homology to CD-4. And if you look at the all the extracellular domains, there are four domains that are almost identical ... they're almost identical to CD-4 and we know that its primary ligand is MHC class 2.
  • So, the original thought was that this is the mechanism of action of LAG-3, but that's not necessarily true. First of the intercellular domain, we have a different domain than most checkpoints that doesn't actually have an item, a domain and again, it has this ipi sequence and a skill motif. And once it's activated, it does inhibit T-cell activity.
SHOW MORE
Related Videos
Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
Ahmad Tarhini, MD, PhD
Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): overall survival and melanoma-specific survival outcomes at 3 years
Long-term follow up for adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma: Final results of the COMBI-AD study
 Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD